

Special Issue

African Swine Fever Virus Prevention and Control

Message from the Guest Editor

Since its introduction into Georgia in 2007, African swine fever virus has spread across both Europe and Asia and has been responsible for the deaths of hundreds of millions of animals. Virulent strains of the virus cause a haemorrhagic fever to occur in domestic pigs and wild boar that is invariably fatal. The main tools missing from the African swine fever control kit are vaccines suitable for preventing disease in both domestic and wild animals. Without such vaccines, it is difficult to envisage how the current epidemic can be brought under control and the disease eradicated. Novel approaches are required, as, to date, inactivated viruses and attenuation through tissue culture passage have not yielded safe and effective vaccines. Due to the severity of the current African swine fever virus epidemic, alternative strategies including prophylaxis may also need to be considered. Deployment of such novel control strategies will require the development of effective implementation strategies based on robust epidemiological modeling.

Guest Editor

Dr. Christopher Netherton
African Swine Fever Vaccinology Group, The Pirbright Institute, Surrey
GU24 0NF, UK

Deadline for manuscript submissions

closed (31 January 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/39062

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).